|
Study: Most angioplasties not needed
[Link is Broken] http://www.cnn.com
POSTED: 3:39 p.m. EDT, March 26, 2007
NEW ORLEANS, Louisiana (AP) — More than half a million people a year with
chest pain are getting an unnecessary or premature procedure to unclog their
arteries because drugs are just as effective, suggests a landmark study that
challenges one of the most common practices in heart care.
The stunning results found that angioplasty did not save lives or prevent
heart attacks in non-emergency heart patients.
An even bigger surprise: Angioplasty gave only slight and temporary relief
from chest pain, the main reason it is done.
“By five years, there was really no significant difference” in symptoms,
said Dr. William Boden of Buffalo General Hospital in New York. “Few would have
expected such results.”
He led the study and gave results Monday at a meeting of the American
College of Cardiology. They also were published online by the New England
Journal of Medicine and will be in the April 12 issue.
Angioplasty remains the top treatment for people having a heart attack or
hospitalized with worsening symptoms. But most angioplasties are done on a
non-emergency basis, to relieve chest pain caused by clogged arteries crimping
the heart’s blood supply.
Those patients now should try drugs first, experts say. If that does not
help, they can consider angioplasty or bypass surgery, which unlike angioplasty,
does save lives, prevent heart attacks and give lasting chest pain relief.
In the study, only one-third of the people treated with drugs ultimately
needed angioplasty or a bypass.
OK to defer angioplasty “You are not putting yourself at risk of death
or heart attack if you defer,” and considering the safety worries about heart
stents used to keep arteries open after angioplasty, it may be wise to wait,
said Dr. Steven Nissen, a Cleveland Clinic heart specialist and president of the
College of Cardiology.
Why did angioplasty not help more?
It fixes only one blockage at a time whereas drugs affect all the arteries,
experts said. Also, the clogs treated with angioplasty are not the really
dangerous kind.
“Even though it goes against intuition, the blockages that are severe that
cause chest pain are less likely to be the source of a heart attack than
segments in the artery that are not severely blocked,” said Dr. David Maron, a
Vanderbilt University cardiologist who helped lead the new study.
About 1.2 million angioplasties are done in the United States each year.
Through a blood vessel in the groin, doctors snake a tube to a blocked heart
artery. A tiny balloon is inflated to flatten the clog and a mesh scaffold stent
is usually placed.
The procedure already has lost some popularity because of emerging evidence
that popular drug-coated stents can raise the risk of blood clots months later.
The new study shifts the argument from which type of stent to use to whether to
do the procedure at all.
It involved 2,287 patients throughout the U.S. and Canada who had
substantial blockages, typically in two arteries, but were medically stable.
They had an average of 10 chest pain episodes a week — moderately severe.
About 40 percent had a prior heart attack more than three months
previously.
“We deliberately chose to enroll a sicker, more symptomatic group” to give
angioplasty a good chance to prove itself, Boden said.
All were treated with medicines that improve chest pain and heart and
artery health such as aspirin, cholesterol-lowering statins, nitrates, ACE
inhibitors, beta-blockers and calcium channel blockers. All also were counseled
on healthy lifestyles — diet, exercise and smoking cessation.
Half of the participants also were assigned to get angioplasty.
After an average of 4½ years, the groups had similar rates of death and
heart attack: 211 in the angioplasty group and 202 in the medication group —
about 19 percent of each.
Heart-related hospitalization rates were similar, too.
Neither treatment proved better for any subgroups like smokers, diabetics,
or older or sicker people.
At the start of the study, 80 percent had chest pain. Three years into it,
72 percent of the angioplasty group was free of this symptom as was 67 percent
of the drug group.
That means you would have to give angioplasties to 20 people for every one
whose chest pain was better after three years — an unacceptably high ratio,
Nissen said.
After five years, 74 percent of the angioplasty group and 72 percent of the
medication group were free of chest pain - “no significant difference,” Boden
said.
The study was funded by the U.S. Department of Veterans Affairs, the
Medical Research Council of Canada and a host of drug companies. Stent makers
refused to help pay for the research, said scientists who led the study.
Animosity among doctors The study renewed a heated animosity between
doctors who perform angioplasty and other heart specialists.
In fact, one who does the procedures and who spoke at a meeting in New
Orleans sponsored by stent maker Boston Scientific Corp. was responsible for the
early release of the study’s results, which were not due out until
Tuesday.
The study “was rigged to fail, and it did,” the Wall Street Journal quoted
Dr. Martin B. Leon of Columbia University telling several hundred of his
colleagues Sunday night.
“A lot of people have been taking shots at us, and we need to go on the
offense for awhile,” the Journal reported Leon said.
He claimed to have inside knowledge of the results because he reviewed the
study for the New England Journal. The journal would not comment, saying the
identity of its reviewers is confidential.
The cardiology college issued a statement saying it was “extremely
disappointed” results were released prematurely, “betraying the confidentiality
of the scholarly process and the professional integrity of the scientific
community.”
The college “will be considering strong sanctions against the individual or
individuals involved,” the statement said.
Shares of Boston Scientific were down $1.15, or nearly 8 percent, to $14.07
in afternoon trading on the New York Stock Exchange. It was a nearly five-year
low for the stock.
Dr. Spencer King of Piedmont Hospital in Atlanta, Georgia, a leading
cardiologist who does many angioplasties, said he was disappointed in the study
results.
“How many patients have interventions in which the only expectation is to
reduce the use of nitroglycerin or to walk a bit faster? Most patients
anticipate a better prognosis and might opt for an extended course of medical
therapy if they believe they are not putting their life at excess risk,” he
wrote in a recent editorial in an American Heart Association journal.
In an interview at the cardiology meeting, King said he recently had
surgery for back pain and did not expect permanent relief but added, “If it only
held up for five years, I wouldn’t be happy about it.”
The new study “should lead to changes in the treatment of patients with
stable coronary artery disease, with expected substantial health care savings,”
Dr. Judith Hochman of New York University wrote in an editorial in the
journal.
Angioplasty costs $30,000 to $40,000. The drugs used in the study are
almost all available in generic form.
Maron, the Vanderbilt doctor who helped lead the study, said people should
give the drugs a chance.
“Often I think that patients are under the impression that unless they have
that procedure done, they’re not getting the best of care and are at increased
risk of having a heart attack and die,” he said.
The study shows that is not true, he said.
|